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Abstract
Formation of new blood vessels is critical for the growth of the
tumor. Angiogenic factor, VEGF, secreted by the tumor cells in-
duces neoangiogenesis. Inhibition of tumor angiogenesis and/or
activation of tumor cell apoptosis will inhibit the growth of the
tumor. In the present study, we have identified that, an ethanolic
extract from the dried rhizome of the plant Curcuma aromatica
(CAE), has potent antiangiogenic and pro-apoptotic activity in
in vivo conditions. The growth of Ehrlich ascites tumor (EAT)
cells and formation of ascites in the peritoneum of EAT bearing
mice was inhibited by CAE. Our results on nuclear staining, for-
mation of the characteristic DNA fragmentation ladder in agarose
gel electrophoresis and downstream activation of an endonuclease
by the CAE in vivo clearly demonstrate the pro-apoptotic activ-
ity induced by CAE. Further, results on decrease in the peritoneal
angiogenesis and microvessel density shows the antiangiogenic po-
tential of the CAE in vivo. The molecular mechanism of antiangio-
genic effect of CAE involves inhibition of VEGF in CAE-treated
mice. Taken together we conclude that the ethanolic extract of
Curcuma aromatica has potent antiangiogenic and pro-apoptotic
properties that can further be developed into potential anticancer
drug.
Keywords: Curcuma aromatica, Ehrlich ascites tumor cells, an-
tiproliferation, antiangiogenesis, proapoptosis.
Introduction
Angiogenesis is a tightly regulated process involving the formation of new
blood vessels from the pre-existing ones and is critical in many physiological
conditions such as pregnancy and wound healing. However, in pathological
conditions such as inflammatory diseases and cancer, a chronic unregulated
angiogenic state often exacerbates the disease (Folkman 1971). Cancer cells
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are known to secrete potent angiogenic growth factors. The levels of these
factors in the serum and urine of cancer patients have been shown to cor-
relate with disease status (Yabushita et al 2003). Among those angiogenic
factors VEGF is one of the best characterized and studied (Ferrara et al
2003). VEGF is an endothelial cell-specific mitogen that promotes many
other events necessary for angiogenesis and plays an important role in the
growth and metastasis of cancer by promoting neovascularization (Terman
and Stoletov 2001). VEGF exerts its actions by binding to two tyrosine ki-
nase receptors, fms-like tyrosine kinase (Flt-1) and fetal liver kinase-1/kinase
insert domain-containing receptor (Flk-1/KDR). Both have been shown to
be almost exclusively expressed in endothelial cells (Griffioen and Molema
2000). It is known that tumors are angiogenesis dependent. Administration
of an angiogenesis inhibitor, which is not directly cytotoxic to tumor cells,
can increase tumor cell apoptosis, decrease VEGF production, and regress
tumor growth either by inhibiting endothelial cell proliferation and formation
of new capillaries feeding the growing tumor or by inducing tumor and/or
endothelial cell apoptosis (Folkman 2003).
The understanding of the mechanisms that regulate angiogenesis and the
discovery and successful use of several angiogenesis inhibitors in animal mod-
els, have led to clinical applications of antiangiogenic therapy. This approach,
in principle, has several advantages over traditional chemotherapy, including
less toxicity and side effects, a general broad spectrum of activity and reduced
risk for development of resistance (Bisacchi et al. 2003).
Today, the number and type of antiangiogenic drugs are continuously
growing. Anticancer properties have been associated with the components
of various natural products including green tea polyphenols, resveratrol, cap-
saicin, taxol, berberine and curcumin. (Wu et al. 1999; Benelli et al. 2002;
Gururaj et al. 2002; Niles et al. 2003; Min et al. 2004). The induction
of apoptosis in tumor cells and inhibition of angiogenesis has been shown to
be the most common anticancer mechanism conjoint by many cancer ther-
apies. Thus to find the potential therapeutic anticancer drugs with potent
and selective pro-apoptotic and antiangiogenic properties would be valuable.
Curcuma aromatica, one of the aromatic and pretty ginger belonging to the
genus Curcuma (Zingiberaceae) is a wild plant of the forests of western ghats
and Bengal in India. It has long been used in traditional medicine for the
treatment of cancer and lung diseases. It also promotes secretion of bile and
has strong antibiotic properties (Behura et al. 2002). Oil extracted from C.
aromatica has been shown to exert antitumor activity on various cancer cells
in vitro and in vivo (Shi et al. 1981; Wu et al. 2000). Anticancer molecule
A- elemene has also been isolated from volatile oil of C. aromatica (Dong et
al. 1997). However, the mechanism responsible for the anticancer activity
is still not clear and needs further investigation. In a screen for naturally
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occurring angiogenic inhibitors, we have identified that an ethonolic extract
from the dried rhizome of the plant C. aromatica has potent antiangiogenic
and pro-apoptotic activity in Ehrlich ascites tumor (EAT) cells model in vivo.
Materials and Methods
Plant Material
Rhizomes of Curcuma aromatica were collected from Western Ghats of Kar-
nataka, India. The rhizomes were air dried in shade and powdered using
commercial blender.
Animals and Chemicals
Swiss albino mice were obtained from animal house, Department of Zoology,
University of Mysore. Mysore, India. Ehrlich Ascites Tumor (EAT) cells were
obtained from American type cell culture, Rockville, USA. Trypan blue and
agarose were procured from Hi- Media, India. Giemsa stain was obtained from
Qualigens, Mumbai; India. Proteolytic inhibitors from Boehringer, Manhiem,
Germany. Alkaline phosphatase- tagged goat anti-rabbit IgG was procured
from Genei, Bangalore, India. Recombinant VEGF165 was used as an antigen
for producing rabbit anti-VEGF polyclonal antibodies. All chemicals and
reagents were of highest grade commercially available.
Preparation of Curcuma aromatica Extract (CAE)
Powdered C.aromatica was extracted (1:1 weight/volume) using 50% ethanol
overnight at room temperature. The residue was removed by filtration and
the extract was allowed to evaporate at 30◦C under reduced pressure in a
rotary evaporator. The extract was then centrifuged at 5,000 rpm for 10min
and the supernatant was dialyzed against distilled water and the pH was
adjusted to 7.0 before storing at 4◦C for all further experiments.
Culture and isolation of Ehrlich ascites tumor (EAT) cells and
ascites fluid
EAT cells are mouse mammary carcinoma cells that grow as ascites tumor
in peritoneal cavity of mice. EAT cells were grown in the peritoneal cavity
of eight to ten weeks old Swiss albino mice by peritoneal transplantation of
0.5ml of cell suspension (5 × 106 cells/ml) in sterile citrated saline (0.9%).
CAE (50µl) was injected into the EAT bearing mice every alternate day after
5 days of tumor transplantation. The weight of the animals was recorded
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from the day of transplantation to sacrifice. The rationale for injecting crude
extract on the 6th day is to stimulate the natural state where a partially or
wholly grown tumor has to be treated. The animals were sacrificed on 13th
day. The cells were harvested in saline after 10-12 days of transplantation
and separated from ascitic fluid by centrifugation at 400 g for 8 minutes.
Contaminating RBCs (if any) during isolation of EAT cells were lysed using
0.4% ammonium chloride. After sacrifice of treated and control EAT bearing
animals, an incision was made in the abdominal region and EAT cells along
with the ascites fluid were harvested into a beaker containing 2ml of saline
and centrifuged at 3000 rpm for 3min. The pelleted cells were resuspended in
saline and placed on ice. Cells were counted and the viability was determined
using trypan blue dye exclusion method. The ascites volume was measured
by subtracting 2ml of volume of saline used for collecting the cells and ascites.
Giemsa and Acridine orange/ethidium bromide staining
Both treated (in vivo) and control cells were fixed in a solution of methanol:
acetic acid (3:1). The fixed cells were smeared on clean microscopic glass
slides and slides were stained with 0.1% Giemsa stain and observed under
Nikon compound microscope.
Nuclear staining (Srinivas et al. 2003) was performed using control as
well as CAE treated EAT cells after washing the cells once with phosphate-
buffered saline (PBS), the cells were stained with 100 µl of a mixture (1:1)
of acridine orange/ethidium bromide. The cells were immediately washed
once with PBS and viewed under Leitz-DIAPLAN florescent microscope and
photographed.
DNA extraction and agarose gel electrophoresis
DNA from control and CAE treated cells was isolated. In brief, cells were
washed twice in PBS at 4◦C and pellets were lysed using SDS (10%) for
30min. Potassium acetate (8M) was added to the supernatant and incubated
for 1h at 4◦C. After spinning at 7000 rpm, an equal volume of distilled phenol,
chloroform and isoamyl alcohol (25:24:1) mixture was added. The mixture
was subjected to centrifugation for 30min at 3000 rpm. The above step was
repeated twice using the supernatant obtained and to the final supernatant,
an equal volume of chloroform was added. After centrifugation at 2000 rpm
for 30min at room temperature, 20µl/ml of RNase was added and incubated
for 30min at 37◦C. Later, 2 volumes of chilled ethanol was added and allowed
to stand at 20◦C overnight. The solution was centrifuged (10, 000 rpm for
1h at 4◦C) and the pellet obtained was dissolved in Tris-EDTA (TE) buffer.
DNA was estimated by recording the absorbance at 260 nm and 280 nm. DNA
was electrophoresed on 2% agarose gel at 50V using TBE buffer. DNA was
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visualized by incorporation of ethidium bromide (1mg/ml) in the gel during
casting and viewed under UV illumination (302 nm). Documentation was
done using BIO-DOC ITTM system.
Endonuclease assay
Endonuclease assay was performed by the method previously described (Stein
et al. 1999) with slight modification. In brief, 1% agarose was prepared in
distilled water to which 10 mg/ml of ethidium bromide and 50mg/ml of heat
denatured salmon sperm DNA was incorporated. Agarose was allowed to
solidify in petriplate and wells were made by sterile cork borer. Cytosolic ex-
tracts were prepared using CAE treated or control EAT cells in a buffer con-
taining 50mM Tris-HCl, pH 7.5, 10mM MgCl2, 1mM CaCl2, 1mM EDTA,
0.25M sucrose, 1mM PMSF, 2mg/ml leupeptin and 10mg/ml aprotenin.
Equal concentration of protein was loaded to each well and incubated for
12 h at 37◦C in a humidified atmosphere. Petriplates were visualized using
transilluminator and the activity of endonuclease was observed as lysis zone
around the well and photographed.
Peritoneal angiogenesis and micro vessel density (MVD)
After harvesting the EAT cells from control or CAE treated animals, the
peritoneum was cut open and the inner lining of the peritoneal cavity was
examined for extent of neovasculature and photographed. Formaldehyde fixed
and paraffin embedded tissues of peritoneum from EAT bearing mice either
treated or untreated with CAE was taken and 5 micron sections were prepared
using automatic microtome (SLEE Cryostat) and stained with Hematoxylin
and Eosin. The blood vessels were counted.
Quantification of VEGF
Indirect ELISA was carried out in 96 well microplates. Each well was coated
with 10µl of ascites fluid collected during the sacrifice of EAT bearing animals
treated and untreated with CAE in coating buffer (50mM carbonate buffer
pH 9.6) and plates were incubated overnight at 4◦C. Subsequently, the wells
were washed and blocked using 5% skimmed milk in PBS for 2 h at 37◦C.
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Figure 1: Effect of CAE on in vivo growth of Ehrlich ascites tumor. Arrows indicate
in vivo treatment A. Control, T. CAE treated.
After washing, anti-VEGF165 antibody was added and the plates were incu-
bated for 2 h at 37◦C. The plates were washed 100µl/well of goat anti-rabbit
IgG conjugated to alkaline phosphatase (1:5000) was added. After 1h at 37◦C,
plates were washed and developed using 100µl of p-nitro-phenyl phosphate
(PNPP). The reaction was terminated by addition of 0.1N NaOH and ab-
sorbance was read at 405 nm in microplate ELISA reader. The experiment
was carried out in triplicates.
Results
Effect of CAE on growth of EAT cells in vivo
Upon treatment of CAE to mice transplanted with EAT cells; there was a
decrease of nearly 50% of the body weight of the animals when compared to
the weight of the control animals (figure 1). This effect of CAE extract on in
vivo growth and proliferation of EAT cells is more evident in the results on
EAT cell number and ascites volume obtained from both control and CAE
treated animals. The results in figure 2 indicate that 2.4 × 109 cells/animal
were obtained from control mice, where as in CAE treated animals the cell
number is 0.4 × 109 cells/animal. The results clearly indicate that CAE in-
hibits proliferation of EAT cells. CAE is not cytotoxic to the EAT cells as
verified by trypan blue exclusion method. In EAT bearing mice; a total vol-
ume of 6 to 7ml of ascites accumulates during the tumor growth period. The
volume of ascites fluid was reduced to 1.5ml in CAE-treated mice resulting
in a 3-fold decrease in ascites volume burden (figure 3).













































Figure 3: CAE inhibits formation of ascites fluid in Ehrlich ascites tumor bearing
mice.
Effect of CAE on apoptosis of EAT cells in vivo
The result on inhibition of growth of EAT cells in vivo clearly indicate
the involvement of the process of apoptosis. EAT cells from CAE treated
mice in vivo or untreated were stained with Giemsa (1%) or ethidium bro-
mide/acridine orange stain (1:1). The results indicated the typical apop-
totic morphology including condensed kidney-shaped nucleus and formation
of apoptotic bodies in CAE treated
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Figure 4: Effect of CAE on EAT cells showing characteristic apoptotic morphology
when stained with giemsa ethidium bromide and acridine orange stain. A (c):
Control, A (t): CAE treated, B (c): Control, B(t): CAE treated. Arrows indicate
membrane blebbing, apoptotic bodies and condensed chromatin.
Figure 5: In vivo effect of CAE on DNA fragmentation of Ehrlich ascites tumor cells.
DNA run and detected on 2% agarose gel electrophoresis. C: DNA from control
EAT cells, T: DNA from CAE treated EAT cells (DNA fragmentation detected
from CAE treated EAT cells).
cells (figure 4A and 4B). DNA fragmentation was also evident as seen in
agarose gel electrophoresis of DNA extracted from CAE treated cells The
DNA from control EAT cells was found to be intact as seen in figure 5.
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Figure 6: CAE treated cytosolic extract of EAT cells showing endonuclease activity
on salman sperm DNA in a dose dependent manner. 1 : 200mg of enzyme source;
2 : 400mg of enzyme source; 3 : 600mg of enzyme source; 4 : 800mg of enzyme
source; 5 : 800mg of cytosolic enzyme source from control EAT cells.
Figure 7: A) Suppression of in vivo angiogenesis by CAE. Peritineal lining of mice
treated with saline (0.9%) or CAE was inspected for angiogenesis. Inhibition of
angiogenesis in CAE-treated mice is evident. B) Formaldehyde fixed, paraffin em-
bedded peritoneum of control as well as CAE treated mice was sectioned (3µ) and
stained with H&E and observed for microvessel density. Decreased MVD in CAE
treated mice peritoneum is evident.

















Figure 8: Effect of CAE on production of VEGF by EAT cells.
The degradation of DNA is by the activation of endonuclease in CAE treated
cells as is evidenced by a clear lysis zone as seen in figure 6, when compared
to the results of control, in which there is no clean lysis zone.
Angioinhibitory activity of CAE
The peritoneal cavity was observed in control as well as treated animals for
the extent of vasculature. The results clearly indicated that there is significant
inhibition of neovascularization in CAE treated animals as compared to the
peritoneum of control animals that show extensive neovasculature as is seen in
figure 7A. The H and E stained sections of the peritoneum further indicated
that there is a reduction in micro vessel density (MVD) (figure 7B), in the
peritoneum of CAE treated animals.
Quantitation of VEGF
The level of angiogenic growth factor, VEGF secreted into ascites during the
growth of EAT cells in vivo either in presence or in the absence of CAE
was measured by indirect ELISA. In the ascites of CAE treated animals, a
significant reduction of VEGF level was observed (figure 8) when compared to
that of VEGF levels in ascites fluid from control mice. While 830-ng/animal
of VEGF was detected in control ascites (6.5ml), 230 ng/animal of VEGF
was detected in CAE treated ascites (1.5ml).
Discussion
Cancer chemoprevention utilizing chemical compounds or natural products
revert or inhibit malignant cell transformation and prevent invasion and
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metastasis would be less painful, more economical and rational approach for
cancer control. The use of natural herbal medicines or dietary agents is being
increasingly utilized as an effective way for the management of many cancer
treatments (Wenzel et al. 2000; Miyoshi et al. 2003).
Recent advances in our understanding of the mechanisms of carcinogenesis
have led to the synthesis of new drugs that can inhibit tumor development in
experimental animals by selective action. Angioinhibition and induction of
apoptosis in tumor cells are the newer strategies for cancer therapy. Thus the
discovery of angiogenic inhibitors with proapoptotic activity would provide an
important therapeutic value. With the goal of finding a potent proapoptotic
and antiangiogenic plant components, we have initiated a screening program
in our laboratory designed to test a wide variety of indigenous plant extracts
for antiangiogenic and proapoptotic activity.
In the present study, we have shown that ethanolic extract of C. aromatica
has potent antiangiogenic and proapoptotic effects in Ehrlich ascites tumor
(EAT) cells in vivo. Various plant components and extracts from plants such
as Taxol, curcumin, Lindera strychifolia, Gleditsia sinensis, Livistona, green
tea are reported to inhibit angiogenesis and induce apoptosis in many tumor
cell types (Lee et al. 2001; Pal et al. 2001; Sartippour et al. 2001; Chow et
al. 2003; Li et al. 2003; Yuasa et al. 2003). We examined, in the present
study, whether CAE can also inhibit angiogenesis and induce apoptosis in
the EAT cell lines in a dose dependent manner. EAT cells treated with CAE
acquired apoptotic morphological features. The extracted DNA showed a
ladder pattern when analyzed by gel electrophoresis and this degradation
is through the activation of endonuclease suggesting an association of the
antineoplastic effect of CAE on EAT cells with the induction of apoptosis.
The morphological changes in CAE treated EAT cells were similar to those
found in the aforementioned plant extracts and which were shown to be a
dose dependent process (data not shown).
There are not many studies focusing on the induction of apoptosis by C.
aromatica. The apoptosis inducing effect of elemene isolated from Curcuma
aromatica oil was first demonstrated in many cancer cell lines (Yang et al.
1996). We showed that administration of CAE inhibited tumor cell growth
in vivo corresponding reduction in cell number in EAT bearing mice. The
rate of tumor growth is dependent on the balance between the proliferative
activity and death rate of the tumor cells. It was suggested that CAE induced
high level of apoptotic activity, which may be linked to slower tumor growth.
Formation of ascites and pleural effusion is a common problem for patients
with advanced stage of cancer (Verheul et al. 2000). These fluid accumula-
tions cause severe symptoms such as abdominal distention, shortness of breath
and fatigue. Our results have clearly shown that CAE inhibits formation of
ascites probably as a consequence of inhibition of VEGF secretion. Preclinical
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models have demonstrated that vascular endothelial growth factor (VEGF)
plays a pivotal role in the accumulation of ascites because it is a potent per-
meability factor. The results obtained in the present study demonstrated
that the expression of VEGF was reduced upon CAE treatment leading to
less accumulation of ascites thereby reducing the tumor burden.
It has been proposed that antiangiogenic drugs may be useful in the pre-
vention of cancer. Recently, antiangiogenic drugs have been shown to eradi-
cate certain mouse tumors and induce long-term tumor dormancy and disease
free survival (Bochm et al. 1997). Our results show that there is angiogen-
esis in mice bearing EAT cells, which is due to the presence of angiogenesis
inducing factors in the ascites fluid. In EAT bearing animals treated with
CAE, showed less peritoneal angiogenesis. Paraffin sections of the peritoneum
stained with H and E showed reduction in microvesssel density count suggest-
ing that CAE has an angioinhibitory activity.
In conclusion, we demonstrate that CAE may act as an angiogenesis
inhibitor and is pro-apoptotic in nature. Further studies are necessary to
identify the active principle responsible for pro-apoptotic and antiangiogenic
actions of CAE. Consequently, the studies of these antiangiogenic and pro-
apoptotic pathways will advance our knowledge and understanding of the
efficacy of many chemo-preventive compounds some of which may become
very potent therapeutic drugs of the future.
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